CyberKnife® as Monotherapy or Boost SBRT for Intermediate or High Risk Localized Prostate Cancer

Clinical Trials, High Risk Prostate Cancer, Intermediate Risk Prostate Cancer

PHENTrials.com Increasing Participation in Prostate Cancer Clinical Trials to Save Lives

NCT Number: NCT01985828
Phase: Not Applicable
Trial Summary: The primary objective of this study is to document the effectiveness of Cyberknife stereotactic body radiotherapy (SBRT) in the treatment of intermediate and high-risk localized pr – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): Advocate Health Care
Acronym
:

Pin It on Pinterest